Anticancer Effects of 15d-Prostaglandin-J2 in Wild-Type and Doxorubicin-Resistant Ovarian Cancer Cells: Novel Actions on SIRT1 and HDAC by de Jong, Edwin et al.
Anticancer Effects of 15d-Prostaglandin-J2 in Wild-Type
and Doxorubicin-Resistant Ovarian Cancer Cells: Novel
Actions on SIRT1 and HDAC
Edwin de Jong
1., Peter Winkel
1., Klaas Poelstra
1,2, Jai Prakash
1,2*
¤
1Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute for Pharmacy, University of Groningen, Groningen, The Netherlands, 2BiOrion
Technologies BV, MediTech Center UMCG, L.J. Zielstraweg 1, Groningen, The Netherlands
Abstract
15-deoxy-delta-12,14-prostaglandin-J2 (15d-PGJ2), an arachidonic metabolite and a natural PPARc agonist, is known to
induce apoptosis in tumor cells. In this study, we investigated new therapeutic potentials of 15d-PGJ2 by determining its
anticancer effects in wild-type and doxorubicin-resistant ovarian carcinoma cells. Despite high expression of resistance-
inducing genes like MDR1, Bcl2 and Bcl-xl, 15d-PGJ2 strongly induced apoptosis in doxorubicin-resistant (A2780/AD) cells
similar to the wild-type (A2780). This was found to be related to caspase-3/7- and NF-kB pathways but not to its PPARc
agonistic activity. 15d-PGJ2 also was able to reduce the doxorubicin resistance of A2780/AD cells at low doses as confirmed
by the inhibition of gene expression of MDR1 (p-glycoprotein) and SIRT1 (a drug senescence gene). We also investigated
effects of 15d-PGJ2 on cell migration and transformation using a wound-healing assay and morphological analyses,
respectively. We found that 15d-PGJ2 inhibited migration most likely due to NF-kB inhibition and induced transformation of
the round-shape A2780/AD cells into elongated epithelial cells due to HDAC1 inhibition. Using a 15d-PGJ2 analog, we found
the mechanism of action of these new activities of 15d-PGJ2 on SIRT1 and HDAC1 gene expressions and enzyme activities.
In conclusion, the present study demonstrates that 15d-PGJ2 has a high therapeutic potential to kill drug-resistant tumor
cells and, the newly described inhibitory effects of this cyclo-oxygenase product on SIRT1 and HDAC will provide new
opportunities for cancer therapeutics.
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Introduction
Prostaglandins (PGs) are a family of biologically active
endogenous metabolites of arachidonic acid. They control a vast
variety of physiological functions such as regulation of smooth
muscle tone, inflammation, cellular growth and differentiation [1].
15-deoxy-D
12,14-prostaglandin J2 (15d-PGJ2) is a dehydration
derivative of PGD2, which is also known as a natural agonist of
the nuclear receptor peroxisome proliferator2activated receptor
gamma (PPARc). 15d-PGJ2 has been reported to display multiple
pharmacological activities (anti-inflammatory, anti-fibrotic and
apoptotic activities) either through PPARc2dependent pathways
or PPARc–independent pathways such as Nuclear Factor-kappaB
(NF-kB)2, Keap-Nrf22, STAT1, and p532dependent pathways
[2,3]. In our recent study, we have shown that 15d-PGJ2 was able
to inhibit tumor progression significantly in vivo in tumor-bearing
mice. Its effectivity was found to be controlled by its strong but
reversible serum albumin binding and by the subsequent
penetration of albumin into the tumors which was dependent on
the tumor vasculature [4]. Also other groups have reported the
anti-tumor activity of 15d-PGJ2 in vivo in different tumor models
[5,6]. These results suggest that a potential use of 15d-PGJ2 for
therapeutic purposes as an anticancer agent can be envisioned.
We have shown that 15d-PGJ2 induces apoptosis in different
cancer cells through PPARc-independent NF-kB and caspase-
dependent pathways [4], as also shown by other studies [7,8].
Knowing the involvement of NF-kB pathway in the regulation of
multidrug resistance (MDR1) and anti-apoptotic genes (Bcl-2 and
Bcl-xl) [9], we now aimed to investigate whether 15d-PGJ2 is
capable of inducing apoptosis in doxorubicin-resistant cancer cells
compared to the wild-type. We further examined whether the
effects induced by 15d-PGJ2 were mediated through PPARc-
dependent and/or NF-kB-dependent pathways. Chu and co-
workers have demonstrated that Silent Information Regulator
Type 1 (SIRT1), a class III histone deacetylase (HDAC), is over-
expressed in various chemoresistant tumors of cancer patients and
inhibition of SIRT1 gene expression leads to decrease in MDR1
expression and increase in drug sensitivity [10]. We therefore
compared the SIRT1 expression in human wild-type and
doxorubicin resistant ovarian cancer cells and examined the
effects of 15d-PGJ2 on this SIRT1 gene expression. During these
experiments, we noticed that 15d-PGJ22treated doxorubicin-
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type. We further investigated this phenotypic change and found
that 15d-PGJ2 induced these effects by inhibiting class-I HDAC
enzymes. Many pharmacological activities of 15d-PGJ2 e.g.
inhibition of PPARc, NF-kB, p53 and Nrf-keap pathways are
induced by making a stable complex with free cysteine in these
proteins through its one of the electrophilic carbon atoms [11]. In
order to determine whether inhibitory effects of 15d-PGJ2 on
SIRT1 and HDACs were also related to the latter mechanism, we
performed several in vitro experiments using an analog of 15d-
PGJ2. Our results show many new activities of this endogenous
arachidonic acid metabolite on cancer cells and illuminate the
mechanism of action of this cyclo-oxygenase product.
Methods
Cell experiments
Wild-type (A2780) and doxorubicin-resistant (A2780/AD)
human ovarian carcinoma cell lines were obtained from University
Medical Centre Groningen, The Netherlands. A2780 and A2780/
AD (doxorubicin-resistant) cell lines were maintained on Dulbec-
co’s modified Eagle’s medium (DMEM, BioWhittaker, Verviers,
Belgium) supplemented with 10% fetal calf serum (FCS) and
antibiotics (penicillin, 50 units/ml plus streptomycin, 50 ng/ml) at
37uC in a humidified incubator containing 5% CO2. A2780/AD
cells were cultured in the presence of doxorubicin (2 mM). Two
weeks before the experiments a separate flask of doxorubicin-
resistant cells was maintained without doxorubicin. These cells
were used for further experiments to avoid the influence of
doxorubicin on our experiments. Since 15d-PGJ2 in vitro looses its
activity in the presence of FCS, all experiments were performed in
FCS-free medium.
Cell viability studies. Cells were seeded into the 96-well
plate as 1610
4 cells/well in 200 ml medium with 10% FCS. After
48 h, cells were washed with serum-free medium and then
incubated with different concentrations of 15d-PGJ2 in serum-free
medium for 48 h. In case of treatment with the irreversible PPARc
antagonist GW9662 (2-chloro-5-nitrobenzanilide, sigma), cells
were pre-incubated with GW9662 (10 mM) for 3 h and then
incubated with a mixture of 15d-PGJ2 (Cayman chemicals, Ann
Arbor, MI) and GW9662 for 48 h. Viability of the cells was
determined using Alamar Blue dye (Serotec, Oxford, UK) which
measures the number of cells on the basis of mitochondrial
activity. After 48 h of the incubation, medium containing the
Alamar blue dye (diluted 1:10) was added to the cells and
incubated for another 4 h. Thereafter the metabolized dye
(fluorescent) was detected with a fluorimeter at Excitation
560 nm and Emission 590 nm.
Caspase 3/7 enzyme assays. Caspase23 and 27 enzymes
activity was determined using Caspase 3/7 Glo assay kit (Promega,
Medison, WI). 1610
4 cells were seeded in 96-well plate in 200 ml
culturing medium. After 48 h, cells were washed with serum-free
medium and incubated with different concentrations of 15d-PGJ2
in 100 ml medium for 5.5 h. Subsequently, 100 ml of the Caspase
3/7-reconstituted reagent was added to the cells and incubated for
30 min in the incubator. The luminescence was determined by a
luminometer (Lumicount, Packard, Meriden, CT).
Annexin V staining. Annexin V staining was performed on
the cells to determine the induction of apoptosis after treatment
with 15d-PGJ2. 1610
4 cells were seeded in an 8-well plate (Lab-
tek, Nunc, Roskilde, Denmark) in 400 ml culturing medium. After
72 h, cells were washed with serum-free medium and incubated
with different concentrations of 15d-PGJ2 in 200 ml medium for
6 h. Subsequently, cells were incubated with 100 ml of the annexin
V-FITC (Roche, Mannheim, Germany) for 15 min at room
temperature, washed and fixed with 4% paraformaldehyde. Then,
cells were mounted with DAPI-containing mounting solution and
staining was examined under a fluorescent microscope.
Gene expression study. 1 610
5 cells per well were seeded
in 12-well plate and cultured for 48 h and then incubated with
different compounds for 48 h. Cells were lysed using a lysis buffer
and RNA was isolated using Absolutely RNA microprep kit
(Stratagene, La Jolla, CA) according to manufacturer’s
instructions. The RNA concentrations were quantitated by a
UV spectrophotometer (NanoDrop Technologies, Wilmington,
DE). Then cDNA was synthesized from equal amounts of RNA
using Superscript III first strand synthesis kit (Invitrogen,
Carlsbad, CA). The primers for human species were obtained
from Sigma-Genosys (Haverhill, UK). The primer sequences are
enlisted in Table 1. Gene expression levels for different genes were
measured by quantitative real-time RT-PCR (Applied Biosystems,
Foster City, CA) using SYBR Green as a fluorescent probe
(Applied Biosystems). Finally, the threshold cycle numbers (Ct)
were used to calculate the gene expression for each target by
normalizing to the house-keeping gene GAPDH.
Transfection and Luciferase assay for NF-kB
activity. NF-kB activity was determined using a Luciferase
reporter based assay as described earlier [4]. In brief, pNF-kB-Luc
(Clontech, Mountain View, CA) containing a specific binding
sequence for NF-kB and an empty Luciferase plasmid, pTAL-Luc
(control) were used for transfection studies. 16104 cells per well
were seeded in white 96-well plates and the transfection of the
plasmids was carried out using FuGENE 6 transfection Reagent
(Roche) after 24 h. Cells were treated with a complex of 0.17 mg
DNA/0.5 ml FuGENE 6 in 100 ml normal media with 10% FCS
for 24 h. Subsequently, cells were washed with serum-free media
and incubated with 15d-PGJ2, BAY 11–7082 (Sigma), ciglitazone
with or without TNF-a (Peprotech, Rocky Hill, NJ) for 4 h.
Thereafter, cells were washed with PBS and lysed with 20 ml cell
lysis buffer, and supplemented with 100 ml Luciferase substrate
(Promega). Luciferase activity was measured by a luminometer
(Lumicount, Packard). The luminescence unit values of pNF-kB-
Luc were neutralized by subtracting the pTAL-Luc values.
Wound healing assay. 1 610
5 cells per well were seeded in
12-well plate and cultured for 48 h in culture medium. Thereafter,
a scratch (wound) was introduced in the confluent cell layer using a
yellow tip placed in a scaffold, allowing standardization of the
scratch. Cells were washed three times with medium to remove
Table 1. Primer sequences for Real-time RT-PCR.
Gene
symbols Forward sequence Reverse sequence
GAPDH ACCCAGAAGACTGTGGATGG TCTAGACGGCAGGTCAGGTC
Bcl-2 GTCTGGGAATCGATCTGGAA AATGCATAAGGCAACGATCC
Bcl-xl TCTGGTCCCTTGCAGCTAGT TCCTTTCTGGGGAAGAGGTT
MDR1 AATGCGCCAAGACTAGGAAG ACCGGAGGATGTTGAACAAG
Sirt1 GCAGATTAGTAGGCGGCTTG TCTGGCATGTCCCACTATCA
HDAC1 GGAAATCTATCGCCCTCACA AACAGGCCATCGAATACTGG
HDAC2 AGACTGCAGTTGCCCTTGAT TGCGCAAATTTTCAAACAAA
HDAC3 TGGCTTCTGCTATGTCAACG CCCGGTCAGTGAGGTAGAAA
Snail ACCCCACATCCTTCTCACTG TACAAAAACCCACGCAGACA
E-cadherin TGCCCAGAAAATGAAAAAGG GTGTATGTGGCAATGCGTTC
doi:10.1371/journal.pone.0025192.t001
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compounds for 48 h and pictures of a defined wound spot were
made with computer-aided phase contrast microscope (Olympus)
at t=0, 24 and 48 h. The area of the wound in the microscopic
pictures was measured using Image J software (National Institutes
of Health, MD) at different time points. The percentage wound
healing after 24 h or 48 h was calculated in relative to the total
wound area at t=0 h of the same wound spot.
S I R T 1a n dH D A C 1e n z y m ea c t i v i t ya s s a y s . SIRT1 and
HDAC1 enzyme inhibition assays were performed to determine the
effect of 15d-PGJ2 on their activities using the commercial kits from
Cayman Chemicals (Ann Arbor, MI). The SIRT1 and HDAC1
enzyme assays were performed in microplates according to the
instructions of the manufacturer. First, assay buffer, SIRT1 or
HDAC1 enzyme and solvent (DMF) or different concentrations of
treatments (15d-PGJ2 or CAY-10410 dissolved in DMF) were mixed.
CAY-10410 (9,10-dihydro-15-deoxy-D
12,14-Prostaglandin J2), an
analog of 15d-PGJ2, was purchased from Cayman chemicals.
Then, the substrate comprised of the p53 sequence Arg-His-Lys-
Lys(e-acetyl)-AMC peptide and co-substrate NAD+ for SIRT1
activity was added to the enzyme mixture and incubated at room
temperature for 45 min. To measure HDAC1 activity, an acetylated
lysine substrate was added to the enzyme mixture and incubated for
30 min at room temperature. Thereafter, the stop/developing
solution, containing a mixture of a developer and nicotinamide
(SIRT1 inhibitor) or Trichostatin A (HDAC1 inhibitor) were added
to the microplate and incubated for 30 min and 15 min, respectively
at room temperature. Deacetylated peptide reacts with the developer
and releases a fluorophore. The fluorophores for both assays were
analyzed using an excitation wavelength of 350 nm and an emission
wavelength of 450 nm. 100% activity of the enzyme was calculated
by incubating with DMF alone and the percentage inhibition of
SIRT1 or HDAC1 activity was calculated relative to the
corresponding solvent concentrations.
Statistical Analyses
Data are presented as mean 6 standard error mean (SEM)
unless otherwise mentioned. The statistical analyses were per-
formed using unpaired two-tailed student’s t-test with p,0.05 as
the minimal level of significance. Cell-viability data were fitted
according to sigmoidal dose-response curve to calculate IC50 using
GraphPad Prism 4 software (La Jolla, CA).
Results
15d-PGJ2 induces apoptosis in both A2780 and A2780/
AD cells PPARc-independently
We confirmed that A2780/AD cells are highly resistant to
doxorubicin as compared to wild-type A2780 cells as the IC50 of
doxorubicin in A2780 and A2780/AD were 1.3 and 120 mM,
Figure 1. Effect of 15d-PGJ2 on the viability of A2780 and A2780/AD cells. (A) Doxorubicin killed A2780 cells completely at 5 mM whereas
A2780/AD cells were highly resistant to doxorubicin. In contrast, 15d-PGJ2 induced cell death in both wild type A2780 (B) and doxorubicin-resistant
A2780/AD (C) cell lines dose-dependently after 48 h. These effects were not PPARc dependent as pre-incubation with an irreversible PPARc
antagonist GW9662 (10 mM) did not block these effects. Data are presented as % of control which was calculated by assuming untreated cells 100%
viable as determined with the alamar blue assay. (D) 15d-PGJ2 enhanced caspase 3/7 enzymes activity (at t=5.5 h) in both cell types in a
concentration-dependent manner. Data represent mean 6 SEM of the average of at least 3 separate experiments. Differences versus controls are
shown as *p,0.05, **p,0.01. (E) Representative photomicrographs showing annexin V staining (green color), an indicator of apoptosis induction, in
A2780 and A2780/AD cells lines after the treatment with 15d-PGJ2 concentration-dependently. DAPI staining (blue color) indicates the total number
of cells. Magnification, 2006. The boxes show the images at higher magnification of 4806.
doi:10.1371/journal.pone.0025192.g001
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c a u s e dc e l ld e a t hi nb o t hA 2 7 8 0c e l l s( I C 50=4.3mM) and
A2780/AD cells (IC50=2.6mM) after 48 h of incubation. 15d-
PGJ2 is a known PPARc agonist but we found that induction of
c e l ld e a t hi nb o t hc e l lt y p e sw a sP P A R c-independent as
pretreatment with the irreversible PPARc antagonist GW9662
did not reverse the effects of 15d-PGJ2 neither in wild-type
(Fig. 1B) nor in resistant (Fig. 1C) cell lines. Furthermore, we
found that 15d-PGJ2 induced apoptosis in both wild-type and
doxorubicin-resistant cells through activation of the caspase
pathway as caspase-3/7 enzyme activities were significantly
induced by 15d-PGJ2 in these cells after 5.5 h of incubation
( F i g .1 D ) .A l t h o u g hA 2 7 8 0 / A D( r e sistant cells) were slightly
more sensitive to 15d-PGJ2 in the cell viability assay, there was
slightly lower induction of caspase activity in these cells
compared to A2780 cells, indicating participation of caspase-
independent assays. The induction of apoptosis in these cells
was also confirmed with annexin V staining, a marker for early
apoptosis. We found that both cell types became positive for
annexin V staining (green color) after the treatment with 15d-
PGJ2 and the number of positive cells was increased at higher
concentrations in both cell lines (Fig. 1E).
15d-PGJ2 induces apoptosis by inhibiting NF-kB pathway
Since the apoptosis induced by 15d-PGJ2 was PPARc-indepen-
dent, we investigated the involvement of the NF-kB pathway, an
important regulator of cell survival and proliferation, in A2780 and
A2780/AD cells using the NF-kB luciferase reporter assay. We
induced the NF-kB activity in these cells with human recombinant
TNF-a which is a direct activator of the NF-kB pathway. We found
that treatment with TNF-a (100 ng/ml) significantly enhanced the
NF-kB activity in both cell types but more pronouncedly in A2780
(13-fold)comparedtoA2780/AD(6.0-fold)(Fig.2A).Treatmentwith
15d-PGJ2 significantly reduced the basal and TNF-a-induced NF-kB
activity in both cell types in a concentration-dependent manner
(Fig 2B and 2C). Yet, the inhibitory effects were stronger in A2780/
AD than A2780 as can be noticed at 2.5 and 5.0 mM concentrations.
These data indicate that apoptosis-inducing effects of 15d-PGJ2 were
mediated through NF-kB pathway. In addition, the PPARc agonist
ciglitazone did not inhibit the basal NF-kB activity at 10 mM
concentration but only at higher concentrations. In further
experiments with ciglitazone we therefore used concentrations that
induce only PPARc-specific effects (EC50=3.0mM) [12] and not
NF-kB-mediated effects. A well-known NF-kB-specific inhibitor, i.e.
BAY-11-7082 inhibited the NF-kB activity in both cell types similarly
Figure 2. Inhibition of NF-kB activity by 15d-PGJ2 in A2780 and doxorubicin A2780/AD cells. To measure NF-kB activity, both A2780 and
A2780/AD cells were transiently transfected with a plasmid containing the NF-kB promoter with a luciferase reporter element (pNF-kB-Luc) for 24 h.
After 24 h, 15d-PGJ2, ciglitazone or BAY-11-7082 were incubated with and without TNF-a for 4 h and then luciferase activity was measured using a
luminescence assay to determine the NF-kB activity. (A) The NF-kB pathway activator, TNF-a (100 ng/ml), induced the NF-kB activity in both cell
types although the increase was higher in A2780 cells. Treatment with 15d-PGJ2 significantly inhibited NF-kB activity in both A2780 (B) and A2780/
AD cells (C) which was more pronounced in TNF-a2activated cells. Ciglitazone inhibited NF-kB only at higher concentrations or in TNF-a2activated
A2780/AD cells. BAY-11-7082 inhibited the NF-kB activity in both cell types with similar efficacy. Data represent the average of at least 3 separate
experiments. Statistical differences versus the respective controls are shown as *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0025192.g002
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effect of NF-kB inhibition in these cells.
15d-PGJ2 reduces the mRNA expression of Bcl-2, Bcl-xl,
MDR1 and SIRT1
After gene expression analyses, we found that A2780/AD cells
had substantial induction of anti-apoptotic genes such as Bcl-2
(120-fold) and Bcl-xl (2-fold) compared to non-resistant A2780
cells (Fig. 3A). Treatment with low concentrations of 15d-PGJ2
(1.0 and 2.5 mM) for 48 h reduced the Bcl-2 and Bcl-xl expression
levels in A2780/AD more strongly than in A2780 cells (Fig. 3A),
which might also explain the higher cell killing potency in A2780/
AD cells. These effects were not due to PPARc agonistic activity or
NF-kB inhibitory effects of 15d-PGJ2 as the well-known PPARc
agonist ciglitazone and selective NF-kB inhibitor only had minor
effect compared to 15d-PGJ2 (Fig. 3A).
In addition, we found that there was an up-regulation of
multidrug resistance (MDR1) and class-III HDAC sirtuin-2
homologue (SIRT1) mRNA expression in doxorubicin-resistant
A2780/AD cells compared to wild-type A2780 cells (Fig. 3B and
3C). The MDR1 levels in A2780 cells were below detection levels.
Interestingly, treatment with 15d-PGJ2 significantly inhibited the
MDR1 expression in the resistant cells and these effects were most
likely attributed to its NF-kB inhibitory effects as BAY-11-7082
also inhibited the expression, whereas ciglitazone had no effect
(Fig. 3B). 15d-PGJ2 also inhibited the SIRT1 expression in both
cell types but these inhibitory effects were not seen with BAY-11-
7082 (Fig. 3C). On the other hand, ciglitazone reduced the SIRT1
expression only in A2780/AD where SIRT1 levels were elevated.
15d-PGJ2 inhibits wound healing process
Since the chemotherapeutic resistant cells may have different
migration behavior than its wild-type version, we furthermore
examined the effect of induced resistance on these parameters
using in vitro wound healing assay. The assay typically measures
migration of cells by measuring the closure of a standard scratch in
time. We found that A2780/AD cells had significantly slower
migration than A2780 cells (Fig. 4A and 4B). 15d-PGJ2 reduced
the migration of both cell types in a dose-dependent manner
(Fig. 4C). Although 15d-PGJ2 reduced the cell viability in A2780/
AD cells at 2.5 mM concentration (Fig. 1C), we did not see cell
death in these experiments which might be due to confluent cell
layer used in these experiments. We found earlier that in confluent
cell layer 15d-PGJ2 had no effect on the cell viability of A2780/
AD (data not shown). Absence of cell death in these experiments is
also apparent in the represented pictures (Fig. 4A). The inhibitory
Figure 3. Effect of 15d-PGJ2 on the gene expression of Bcl-2, Bcl-xl, MDR1, and SIRT1. (A) A2780/AD cells had higher gene expression of
Bcl-2 and Bcl-xl compared to A2780 cells. Effects of 15d-PGJ2, ciglitazone and BAY-11-7082 on the gene expression were determined after 48 h of
incubation in both cell types. A2780/AD cells also had higher expression of MDR1 (B) and SIRT1 (C) compared to A2780 cells. Mdr1 gene expression
was not detectable (ND) in A2780 cells. Effects of 15d-PGJ2, ciglitazone and BAY-11-7082 on MDR1 expression were determined only in A2780 cells (B)
while the effects on SIRT1 expression were measured on both cell types (C). Data represent mean 6 SEM for at least 3 experiments. Statistical
differences versus the respective controls are shown as *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0025192.g003
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not with ciglitazone indicating the effects of 15d-PGJ2 might be
due to its NF-kB inhibitory effects.
Effect of 15d-PGJ2 on cell morphology
During the incubations with 15d-PGJ2, we noticed that cells
were transformed into enlarged and elongated cells. This
phenotypic change was most prominently visible in the dox-
resistant A2780/AD cells. These cells were initially rounded and
shrunk but after transformation they attained more cytoplasm with
distinct cellular boundaries and displayed an appearance of
epithelial-like structure (Fig. 5A). Treatment with ciglitazone or
BAY-11-7082 induced no change in cell morphology indicating no
role of PPARc and NF-kB pathways. Since it was reported in the
literature that the HDAC inhibitor trichostatin A could transform
the ovarian carcinoma cells [13], we treated cells with trichostatin
A and found that cells got transformed in a similar way as with
15dPGJ2 (Fig. 5A). Although A2780 cells also looked more
stretched with 15d-PGJ2 and trichostatin A, differences versus
control cells were not large (Fig. 5B).
Since the transformation of cells might be related to epithelial-
mesenchymal transition (EMT) process, we examined the
expression of snail and e-cadherin transcripts and found that the
ratio of snail to e-cadherin was increased in both cell types after
the exposure of 2.5 mM 15d-PGJ2 though the differences were not
statistically significant. These data indicate that change in cell
morphology induced by 15d-PGJ2 might be due to induction of
the EMT process.
15d-PGJ2 inhibits HDAC 1, 2 and 3 mRNA expression
Since the cell transformation effects of 15d-PGJ2 were also
induced by the HDAC inhibitor, we examined the effect of 15d-
PGJ2 on HDAC in both cell types. First, we compared the mRNA
levels of HDAC1, 2 and 3 in A2780 and A2780/AD cells and
found that HDAC2 was significantly downregulated in the
resistant cells compared to wild-type cells (Fig. 6A). Treatment
with 15d-PGJ2 inhibited the HDAC1, 2 and 3 mRNA expressions
in both cell types dose-dependently (Fig. 6B and 6C). The effects
were most pronounced in resistant cells. These inhibitions were
not found with ciglitazone and BAY-11-7082, yet there was an
increase in HDAC1 expression after NF-kB inhibition with BAY-
117082.
15d-PGJ2 inhibits SIRT1 and HDAC enzymes activities due
to its electrophilic carbon atoms
Since we found that 15d-PGJ2 could inhibit the gene expression
of SIRT1 and other HDACs, we wondered whether 15d-PGJ2 was
able to inhibit these enzyme activities directly. We used a p53
sequence-based substrate (Arg-His-Lys-Lys(e-acetyl)-AMC) assay
to determine SIRT1 activity and for HDAC1 we used an
acetylated lysine substrate-based assay. In order to find whether
the C9 electrophilic carbon atom is responsible for the activity, we
included the 15d-PGJ2 analog CAY-10410 that lacks the
electrophilicity at C9 (Fig. 7A). We found that 15d-PGJ2 inhibited
the SIRT1 activity dose-dependently with up to 71% inhibition
whereas CAY-10410 only showed only moderate inhibition of
23% while ciglitazone showed no inhibition at all (Fig. 7B). In the
Figure 4. Effect of 15d-PGJ2 on wound healing process. To determine the effects of 15d-PGJ2 on cell migration, a wound healing assay was
performed on A2780 and A2780/AD cells as described in materials and methods. (A) Representative pictures showing the scratch (wound) at t=0 h
and t=48 h with/without different treatments. A mark (visualized in these pictures on the upper or bottom side) was placed to locate the same area
on the scratch, pictures were made using an inverted microscope and the open area was calculated at the indicated time points. Magnification, 406.
(B) The graph shows % wound healing in A2780 and A2780/AD cells without treatments. A2780 cells had higher migration rate compared to A2780/
AD cells. Data represent mean 6 SEM for 3 different experiments. **p,0.01 versus A2780/AD. (C) Treatment with 15d-PGJ2 and BAY-11-7082
inhibited the wound healing response after 48 h incubations while ciglitazone did not show any inhibitory effects. Data represent mean 6 SEM for 3
different experiments. *p,0.05 and **p,0.01 versus values at t=0 h.
doi:10.1371/journal.pone.0025192.g004
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10410 and ciglitazone did not show any inhibition (Fig. 7C).
We further examined whether the effects of 15d-PGJ2 were
displayed due to the C9 electrophilic atom, we tested the effects of
CAY-10410, lacking electrophilicity at C9 carbon atom, on cell
viability and transformation. We found that CAY-10410 did
neither induce any cell death nor transformation of the cells
(Fig. 7D and 7E).
Discussion
In the present study, we have demonstrated the effects of 15d-
PGJ2, a product of cyclo-oxygenase activity and as an endogenous
PPARc agonist, on apoptosis, drug resistance, cell migration and
transformation of cancer cells. We examined its effects on wild-
type as well as doxorubicin-resistant ovarian cancer cells. We
hypothesized that if 15d-PGJ2 affects multi-drug resistant tumor
cells, it is important to explore its mechanism of action because it
may lead to new targets for intervention in therapy-resistant cells.
In literature, multiple mechanisms of action of 15d-PGJ2 have
been shown which are related to either PPARc2dependent
pathways or PPARc2independent pathways such as NF-kB, p53,
and Nrf2/keap1 [11]. In the present study, we have profound
effects of this cyclo-oxygenase product on tumor cells and we
showed that these different actions are mediated by different
mechanisms of action of 15d-PGJ2. Most importantly, we
discovered the new mechanisms of action of 15d-PGJ2 i.e.
inhibition of SIRT1 and other histone deacetylases (HDAC)
which regulate multiple mechanisms in cancer cells. We
furthermore elucidated that 15d-PGJ2 inhibits the activity of these
enzymes due to its electrophilic C9 carbon atom.
Development of resistance against chemotherapy is a big
challenge in medicine and therefore new therapeutics are a
prerequisite for resistant cancers [14]. The apoptosis-inducing
effects of 15d-PGJ2 through PPARc-independent pathways, in
non-resistant tumor cells, have been well reported in many studies
using different assays such as caspase, annexin V staining and
mitochondrial activity assays [4,6,15]. However, in this study we
show that 15d-PGJ2 can also induce apoptosis in doxorubicin2
resistant A2780/AD cells through PPARc-independent pathways.
Tumor cells can induce drug resistance through inducing drug
efflux pump (p-glycoprotein or MDR1), by up-regulation of anti-
apoptotic genes (Bcl-2, Bcl-xl) or by other mechanisms [16].
Indeed, we found up-regulation of MDR1, Bcl-2 and Bcl-xl
expression in doxorubicin-resistant A2780/AD cells compared to
the non-resistant cells (Figure 3A, 3B). Since 15d-PGJ2 induced
apoptosis in these A2780/AD cells, it is apparent that up-
regulation of these pathways does not affect the activity of 15d-
Figure 5. Effect of 15d-PGJ2 on cell morphology. (A) Representative pictures showing the change in cell morphology of A2780/AD after
incubation with 15d-PGJ2 (2.5 mM) and trichostatin A (70 nM). In contrast, other treatments such as ciglitazone and BAY-11-7082 did not affect the
morphology. Arrows point out the transformed cells that had more cytoplasm and epithelial cells structure. Magnification, 2006(B) Representative
pictures of A2780 cells after incubation with different treatments. Treatment with 15d-PGJ2 (2.5 mM) and trichostatin A (70 nM) led to a clear increase
in the cytoplasm. Magnification, 2006(C) Ratio of snail to e-cadherin gene expression in A2780 and A2780/AD cells. Data represent mean 6 SEM for 3
experiments.
doi:10.1371/journal.pone.0025192.g005
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MDR1, Bcl-2 and Bcl-xl in the resistant cells. These data suggest
that 15d-PGJ2 is in potential to kill a variety of chemotherapy
resistant tumor cells.
NF-kB is a ubiquitous transcription factor that regulates cell
proliferation and cell survival by controlling the caspase family of
enzymes [9]. 15d-PGJ2 directly inhibits the NF-kB activity by
inhibiting the degradation of IkB that prevents translocation of
NF-kB units into the nucleus [8]. In our previous study, we have
shown that 15d-PGJ2 inhibited NF-kB in different tumor cells [4]
and in this study we therefore compared the effect of 15d-PGJ2 on
this pathway in doxorubicin-resistant and non-resistant tumor
cells. Although 15d-PGJ2 inhibited NF-kB activity in both A2780
and A2780/AD cells, the effects were significantly more
pronounced when this pathway was activated by TNF-a. Using
a well-known PPARc agonist, ciglitazone, or the irreversible NF-
kB2specific inhibitor, BAY-11-7082, we examined whether the
effects of 15d-PGJ2 were mediated through PPARc or NF-kB.
Our data demonstrate that inhibition of MDR1 gene expression
and cell migration in wound healing assay by 15d-PGJ2 were most
likely mediated through the NF-kB pathway as inhibition of this
pathway using BAY-11-7082 resulted in similar effects. Also other
studies found that NF-kB can induce MDR1 expression [17] and
cell migration and metastasis in tumor cells [18]. In contrast, no
effects of the PPARc agonist ciglitazone were found. Apparently,
there was almost no participation of PPARc in these effects. These
data indicate that 15d-PGJ2 may diminish drug resistance and
inhibit tumor metastasis due to its NF-kB inhibitory action. These
effects were already seen at low concentrations, indicating that this
activity of 15d-PGJ2 might be physiologically relevant.
SIRT1 is a NAD
+-dependent deacetylase which deacetylates
histones and nonhistone proteins and has been shown to delay
senescence [19]. Chu et al have shown that ectopic over-
expression of SIRT1 induces the expression of MDR1 and leads
to resistance to chemotherapy in tumor cells [10]. In line with
these data, we also found an enhanced SIRT1 expression in the
resistant cells. This increase in SIRT1 was significantly reduced by
15d-PGJ2. This inhibitory effect might be due to the PPARc
agonistic activity as the PPARc agonist, ciglitazone, also inhibited
the expression of SIRT1 in the resistant cells. In accordance with
this, a recent study has demonstrated that PPARc and SIRT1
mutually regulate each other and PPARc inhibits the SIRT1
activity [20]. Inhibition of SIRT1 by 15d-PGJ2 was not due to its
NF-kB inhibiting activity as BAY-11-7082 did not inhibit the
SIRT1 expression. In contrast, it led to an increase in SIRT1
expression in A2780 cells. This increase might be due to a
feedback loop between SIRT1 and NF-kB as over-expression of
SIRT1 is known to inhibit NF-kB by deacetylating RelA/p65 unit
[21]. In addition, next to its effect on gene expression, 15d-PGJ2
also strongly inhibited the SIRT1 enzyme activity in vitro
Figure 6. Effect of 15d-PGJ2 on the gene expression of HDAC1, 2, and 3. (A) Real-time qPCR data show the differences between the basal
gene expression levels of HDAC 1, 2, and 3 in A2780 and A2780/AD cells. **p,0.05 versus A2780 cells. Effect of different treatments on HDAC genes
were determined in A2780 (B) and A2780/AD cells (C) after 48 h incubation. Data represent mean 6 SEM for 3 separate experiments. Statistical
differences versus the respective controls are shown as *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0025192.g006
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pathways. This is the first study showing the effects of this cyclo-
oxygenase product on SIRT1 and since SIRT1 blocks senescence,
cell differentiation and stress-induced apoptosis and promotes cell
growth and drug resistance [19], the effects of 15d-PGJ2 shown in
this study on SIRT1 are physiologically very relevant.
We observed a change in cell morphology after treatment with
15d-PGJ2, which led us to the hypothesis that 15d-PGJ2 was not
only inhibiting class III HDAC (SIRT1) activity but also class I
HDAC enzymes. It was known that an inhibitor of class I HDAC
activity, trichostatin A, can induce transformations in cell
morphology [13] which were quite similar to the changes seen
in the present study with 15d-PGJ2 (Fig. 5). This was confirmed
when 15d-PGJ2 was found to inhibit HDAC 1, 2 and 3 gene
expression levels in both cell types and also reduced the
deacetylase activity of HDAC1 in vitro. The HDAC inhibition
was exclusive for 15d-PGJ2 as ciglitazone and BAY-11-7082 did
not inhibit the expression of these genes. Since the potency of 15d-
PGJ2 on SIRT1 gene expression and activity was higher than its
potency on HDAC1 gene expression and activity, the pharmaco-
logical effects of 15d-PGJ2 at lower doses may be predominated by
its SIRT1-inhibitory actions. Moreover, the morphological
changes might be related to the induction of EMT process as
the snail to e-cadherin ratio was induced with 15d-PGJ2. Snail is
the transcription factor for suppressing e-cadherin expression, and
the higher ratio between them has been described earlier
indicating the overall lower survival of patients with ovarian and
breast carcinoma [22,23].
Many studies have shown that 15d-PGJ2 exhibits most of its
pharmacological effects by conjugating to a nucleophile moiety in
a protein such as a free cysteine group, through a Michael addition
reaction [11]. In this study, we demonstrated that electrophilic
carbon atoms of 15d-PGJ2 were also responsible for the inhibitory
effects on SIRT1 and HDAC1 enzymes. Using an analogue of
15d-PGJ2,, CAY-10410, that lacks electrophilicity at the C9 atom,
we revealed that HDAC inhibition was completely dependent on
the C9 atom while SIRT1 inhibition was mostly dependent on C9
but also slightly on the C13 atom as CAY-10410, having
electrophilicity at C13, also showed some degree of SIRT1
inhibition. Lack of activity of CAY-10410 in cell viability assays
and cell transformation indicates that electrophilicity of C9 atom is
highly important for the major activities of 15d-PGJ2.
In summary, 15d-PGJ2 is a strong apoptotic2inducing
arachidonic metabolite which induced cell death in doxorubi-
Figure 7. Effect of 15d-PGJ2 and its analog CAY-10410 on SIRT1 and HDAC1 activity. (A) Chemical structures of 15d-PGJ2 (15-deoxy-D
12,14-
Prostaglandin J2) and its analog CAY-10410 (9,10-dihydro-15-deoxy-D
12,14-Prostaglandin J2). Asterisk indicates the electrophilic carbon atoms which
might be involved in Michael addition reaction. Panel (A) and (B) show the concentration-dependent effects of 15d-PGJ2, CAY-10410 and ciglitazone
on the deacetylase activity of SIRT1 and HDAC1, respectively using in vitro enzyme assays.
#P,0.01 versus ciglitazone,
{p,0.05 and
{{p,0.01 versus
CAY-10410. (D) Effect of CAY-10410 on the cell viability of A2780 and A2780/AD cells as measured with an alamar blue assay. (E) Treatment with CAY-
10410 (2.5 mM) did not induce cell transformation after 48 h incubation. Magnification, 2006.
doi:10.1371/journal.pone.0025192.g007
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resistant cells. Many effects of 15d-PGJ2 were induced through its
NF-kB inhibiting activity and were not due to its PPARc-agonistic
activity. In addition to this, we found direct effects on SIRT1 and
HDAC1 expression and activity, mediated by its C9 atom, which
represent new mechanisms of action of this endogenous mediator.
These intracellular effects affected tumor cell migration, transfor-
mation, and attenuated MDR1 gene expression and thus therapy
resistance. The present study will help better understand the
complexity of actions of this endogenous metabolite. Moreover,
the knowledge on its inhibitory activity on SIRT1 and HDAC
may help in designing their new inhibitors. As showed in our
recent study that pharmacokinetics of 15d-PGJ2 is controlled by its
albumin binding and tumor vasculature [4], in order to apply 15d-
PGJ2 for therapeutic purpose it would be highly interesting to
employ a tumor drug delivery approach to improve its
pharmacokinetics and to achieve tumor-specific effects.
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